EU Forges Landmark Agreement on Vital Medicines to Bolster Supply and Innovation

Brussels, Belgium – After extensive negotiations, European Union policymakers have reached a pivotal political agreement on a sweeping reform of the bloc's pharmaceutical legislation, designed to address critical medicine shortages, fortify domestic production, and spur innovation in the healthcare sector. The comprehensive overhaul, representing the most significant changes to the regulatory framework in over two decades, aims to ensure timely access to essential treatments for all European citizens while enhancing the EU's strategic autonomy in medicine supply.

The provisional deal, finalized on December 11, 2025, comes amidst increasing concerns over the continent's reliance on non-EU countries for vital medications and their active ingredients, as well as the pressing need to combat antimicrobial resistance. The new legislation is expected to formally enter into force in 2026, initiating a two-year transition period for member states to align their national laws and for implementation guidelines to be established by the European Commission, the European Medicines Agency (EMA), and national authorities.

Securing Europe's Medicine Cabinet

A central pillar of the new legislation is the concerted effort to prevent medicine shortages, which have intermittently affected European pharmacies and hospitals, impacting critical treatments like antibiotics, painkillers, and fever syrups for children. The agreement seeks to diminish dependency on external suppliers, particularly from China and India, by incentivizing increased pharmaceutical production within the EU.

Under the new rules, public procurement will favor medicines produced in Europe, with contracting authorities able to reward suppliers proportionally to the share of medicinal products and their active pharmaceutical ingredients manufactured within the EU. This "Buy European" approach aims to strengthen secure supply chains and foster a more robust domestic manufacturing base. Furthermore, the legislation establishes a framework for "strategic projects" located in the EU, designed to create, modernize, and expand manufacturing capacity. Companies benefiting from national or EU financial support for these projects will be obligated to prioritize supply to the EU market. Member states will also engage in enhanced coordination on contingency stockpiling, exchanging information and collaborating on efforts to prevent shortages in one country from creating scarcity in another.

Catalyzing Innovation and Streamlining Pathways

Beyond supply security, the reform package aims to boost pharmaceutical innovation and streamline regulatory processes, thereby accelerating patient access to novel and breakthrough therapies. The EMA's scientific committee structure for human medicines is expected to be simplified, potentially reducing assessment timelines for marketing authorization opinions from 210 to 180 days.

The legislation also introduces stronger incentives for the development of new products, with a particular focus on areas of unmet medical need and rare diseases. For orphan medicinal products, strategic projects and collaborative procurement opportunities will be available. This push for innovation is balanced with efforts to ensure a well-functioning internal market and enhance affordability, seeking to strike a balance between incentivizing research and ensuring equitable access across the EU.

A New Front in the Fight Against Antimicrobial Resistance

One of the most critical aspects of the new legislation is its dedicated focus on combating antimicrobial resistance (AMR), a growing global health threat. To stimulate the research and development of novel antimicrobials, the reform introduces Transferable Exclusivity Vouchers (TEVs). This mechanism allows companies that develop a new antibiotic to extend the market exclusivity for that antibiotic for a limited period, or to transfer this exclusivity right to another drug. The intention behind TEVs is to make the development of urgently needed new antibiotics more financially attractive, providing a predictable revenue stream to incentivize investment in a challenging research area.

However, the effectiveness and equity of the TEV system have been subjects of debate among stakeholders. While some welcome the initiative, concerns have been raised that the proposed TEV durations, modulated by pathogen priority, might be insufficient to stimulate significant investment, especially given the stringent criteria for "critical" pathogens. Critics also highlight the potential for TEVs to lead to higher costs for healthcare systems and argue that a more holistic approach combining various "push" and "pull" incentives, such as direct funding and milestone prizes, may be necessary.

Greening Pharmaceutical Production

In a significant move towards environmental sustainability, the new legislation reinforces requirements for Environmental Risk Assessments (ERAs) for medicines. This aims to mitigate the potential adverse impact of pharmaceutical production, usage, and disposal on the environment and public health. Companies will be required to conduct ERAs for their products as part of marketing authorization applications, proposing measures to minimize the quantity of products released into the environment and outlining appropriate disposal methods.

For antimicrobials, the ERA must specifically evaluate the risk of AMR selection in the environment, encompassing the entire manufacturing supply chain both inside and outside the EU, as well as the use and disposal of the antimicrobial by healthcare professionals and patients. This environmental dimension reflects the EU's broader commitment to the European Green Deal and recognizes the interconnectedness of human health, animal health, and ecosystem well-being in the context of AMR.

Looking Ahead

The political agreement now awaits formal approval by both the European Parliament and the Council before the new rules can fully enter into force. While typically a formality following such a comprehensive provisional deal, the subsequent implementation phase will be crucial. The pharmaceutical industry has expressed some apprehension regarding the potential impact of certain aspects of the reform, particularly concerning intellectual property rights and the complexity of new regulatory requirements, warning that these could undermine Europe's competitiveness and slow the development of new treatments.

Despite these concerns, EU officials emphasize that the reform strengthens competitiveness and innovation while maintaining strict safety standards. The overarching goal remains to create a more resilient, accessible, and innovative pharmaceutical landscape for Europe, ensuring that patients across the bloc have timely and equitable access to safe, effective, and affordable medicines for decades to come.